مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

لائحة الأدوية الأساسية 2018


Foreword
 
Essential medicines as defined by the World Health Organization (WHO) are “those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility”.
 
The WHO Model list of Essential Medicines revised every two years provides a template and serves as a guide for countries to prepare their own lists taking into consideration local priorities.

Based on the current version of the WHO Model List of Essential medicines 20th edition published in 2017, the Ministry of Public Health in Lebanon through the Quality Assurance of Pharmaceutical Products Program prepared the National List of Essential Medicines EML 2018, four years after the last edition in 2014. The EML 2018 contains around 350 medicinal products and was prepared over one year by a Committee of Experts.

The EML is aligned with the National Drug Formulary and National Health Programs such as EIP Mother & Child, TB Control, HIV/AIDS, Malaria, National Mental Health Program and Primary Healthcare. The formulation and strengths of medicines listed in the EML are those mentioned under these National Health Programs and National Drug Formulary.
 
The Lebanese EML 2018 contains a core list and complementary list:

The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.
 
The list is divided into 30 sections related to the main Therapeutic classes of medicines and arranged in three columns;
 
  1. INN of the medicine,
  2. Dosage form and strength of the medicine
  3. Official Status of the medicine 
 
Medicines and dosage forms are listed in alphabetical order within each section with no implication of preference for one form over another.
 
The following symbols are used in the list to indicate the status of the medicine:
 
R: Registered drug in the Ministry of Public Health
NR: Non Registered drug in the Ministry of Public Health
HIV: included in the HIV Program
M: included in the MALARIA Program
NMHP: included in the NATIONAL MENTAL HEALTH Program
TB: included in the TUBERCULOSIS Program
U: provided through UNICEF Program
Y: provided through YMCA Program
[a]: indicates that there is an age or weight restriction on use of the medicine.
 
An index listing the Medicines by alphabetical order is available at the end of the document facilitating retrieval of information and easy reference.
 
We hope that all health providers would embrace this document as important tool for management of medicines and rationalizing prescription in the country. The EML 2018 welcomes comments from healthcare professionals; such comments help us to ensure that the National Essential medicines list remains relevant to practice.
 
The list can be accessed from the official website of the Ministry of Public Health:  www.moph.gov.lb
 

List of Essential Medicines Lebanon 2018
    1
    ...
التصنيف العلاجي الاسم أساسي / جنيسي ↑ التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
A10BD20 SYNJARDY B Empagliflozin - 5mg, Metformin HCl - 1000mg 5mg/1000mg Tablet, film coated 3,156,820 L.L
M01AE11 SURGAM B Tiaprofenic acid - 300mg 300mg Tablet 440,780 L.L
R03AK06 SERETIDE DISKUS 100 B Salmeterol (xinafoate) - 50mcg/inhalation, Fluticasone propionate - 100mcg/inhalation Inhalation powder 2,276,469 L.L
N04BA02 SINEMET B Levodopa - 250mg, Carbidopa - 25mg Tablet, scored 1,283,690 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 20mg 20mg Injectable powder for suspension+diluent L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 30mg 30mg Injectable powder for suspension+diluent L.L
N04BA02 SINEMET B Levodopa - 100mg, Carbidopa - 25mg Tablet 2,742,335 L.L
R03AK06 SERETIDE DISKUS 250 B Salmeterol (xinafoate) - 50mcg/inhalation, Fluticasone propionate - 250mcg/inhalation Inhalation powder 2,830,132 L.L
R03AK06 SERETIDE DISKUS 500 B Salmeterol (xinafoate) - 50mcg/inhalation, Fluticasone propionate - 500mcg/inhalation Inhalation powder 3,199,689 L.L
N04BB01 SYMMETREL B Amantadine - 100mg 100mg Capsule 568,253 L.L
N04BC05 SIFROL B Pramipexole (dihydrochloride monohydrate) - 0.18mg 0.18mg Tablet 631,606 L.L
N04BC05 SIFROL B Pramipexole (dihydrochloride monohydrate) - 0.7mg 0.7mg Tablet 2,478,046 L.L
N04BC05 SIFROL ER B Pramipexole (dihydrochloride monohydrate) - 0.75mg 0.75mg Tablet, extended release 942,034 L.L
R03AK07 SYMBICORT B Formoterol fumarate dihydrate - 4.5mcg/Inhalation, Budesonide - 160mcg/Inhalation Inhalation powder 3,378,420 L.L
N04BC05 SIFROL ER B Pramipexole (dihydrochloride monohydrate) - 0.375mg 0.375mg Tablet, extended release 473,033 L.L
R03AK07 SYMBICORT TURBUHALER B Formoterol fumarate dihydrate - 4.5mcg/inhalation, Budesonide - 160mcg/inhalation Inhalation powder 1,689,210 L.L
R07AA01 SURVANTA B Colfosceril palmitate - 200mg/8ml 200mg/8ml Suspension 36,957,499 L.L
N04BC05 SIFROL ER B Pramipexole (dihydrochloride monohydrate) - 1.5mg 1.5mg Tablet, extended release 1,847,783 L.L
R03AK07 SYMBICORT B Formoterol fumarate dihydrate - 9mcg/Inhalation, Budesonide - 320mcg/Inhalation Inhalation powder 3,378,420 L.L
A07BC05 SMECTALIA B Diosmectite - 3g/sachet 3g/sachet Powder for suspension 935,570 L.L
A07BC05 SMECTALIA STRAWBERRY B Diosmectite - 3g/sachet 3g/sachet Powder for suspension 935,570 L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule 54,006,801 L.L
L01EX01 SUTENT B Sunitinib maleate - 25mg 25mg Capsule 98,852,769 L.L
A07EC02 SALOFALK B Mesalazine - 500mg 500mg Tablet, enteric coated 2,874,479 L.L
L01EX01 SUTENT B Sunitinib maleate - 50mg 50mg Capsule 197,706,574 L.L
A07EC02 SALOFALK B Mesalazine - 1000mg 1000mg Granules, gastro-resistant, prolonged release 3,874,298 L.L
R03AL06 SPIOLTO RESPIMAT B Olodaterol HCl - 2.5mcg/puff, Tiotropium bromide monohydrate - 2.5mcg/puff Inhalation solution 5,087,788 L.L
L01EX05 STIVARGA B Regorafenib - 40mg 40mg Tablet, film coated 262,387,816 L.L
A07EC02 SALOFALK 500 B Mesalazine - 500mg 500mg Suppository 677,297 L.L
A07EC02 SALOFALK B Mesalazine - 1g 1g Suppository 3,948,209 L.L
    1
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025